Nomura Holdings Inc Bei Gene, Ltd. Transaction History

Nomura Holdings Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $215,530 - $274,500	1,000 New	1,000 $215,000
Q3 2022 Nov 15, 2022	SELL	$131.8 - $202.24 $527,200 - $808,960	-4,000 Reduced 60.42%	2,620 $353,000
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $157,443 - $280,865	1,300 Added 24.44%	6,620 $1.07 Million
Q1 2022 May 18, 2022	SELL	$146.52 - $269.56 $2.31 Million - $4.26 Million	-15,798 Reduced 74.81%	5,320 $1.1 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $3.8 Million - $5.96 Million	15,298 Added 262.85%	21,118 $5.72 Million
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $58,550 - $73,402	-200 Reduced 3.32%	5,820 $2.08 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $307,555 - $450,901	-1,180 Reduced 16.39%	6,020 $2.01 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $796,716 - $1.14 Million	3,600 Added 100.0%	7,200 $1.84 Million
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $286,560 - $413,028	3,600	3,600 $352,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.